Anticholesteremic agent: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett (Added Uses) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
In | {{subpages}} | ||
In [[medicine]], an '''anticholesteremic agent''' is any drug used to lower the serum [[cholesterol]] in the treatment of [[hypercholesterolemia]]." | |||
==Classification== | ==Classification== | ||
===Hydroxymethylglutaryl-coenzyme A reductase inhibitors (Statins)=== | ===Hydroxymethylglutaryl-coenzyme A reductase inhibitors (Statins)=== | ||
The [http://www.ahrq.gov/clinic/uspstfix.htm U.S. Preventive Services Task Force (USPSTF)] estimated that after 5 to 7 years of treatment with [[statin]]s, the [[relative risk reduction]] of coronary heart disease events is decreased by approximately 30%<ref name="pmid11306236">{{cite journal |author=Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN |title=Screening and treating adults for lipid disorders |journal=American Journal of Preventive Medicine |volume=20 | | The [http://www.ahrq.gov/clinic/uspstfix.htm U.S. Preventive Services Task Force (USPSTF)] estimated that after 5 to 7 years of treatment with [[statin]]s, the [[relative risk reduction]] of coronary heart disease events is decreased by approximately 30%<ref name="pmid11306236">{{cite journal |author=Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN |title=Screening and treating adults for lipid disorders |journal=American Journal of Preventive Medicine |volume=20 | Suppl |pages=77–89 |year=2001 |pmid=11306236 |doi=}}</ref><ref name="webPignone">{{cite web |url=http://www.ahrq.gov/clinic/ajpmsuppl/lipidrr.htm |title=Screening for Lipid Disorders: Recommendations and Rationale |accessdate=2007-10-17 |format= |work=}}</ref>. More recently, a [[meta-analysis]] reported an almost identical [[relative risk reduction]] of 29.2% in low risk patients treated for 4.3 years <ref name="pmid17130382">{{cite journal |author=Thavendiranathan P, Bagai A, Brookhart M, Choudhry N |title=Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials |journal=Arch Intern Med |volume=166 |pages=2307-13 |year=2006 |pmid=17130382|doi=10.1001/archinte.166.21.2307}}</ref>. A [[relative risk reduction]] of 19% in coronary mortality was found in a [[meta-analysis]] of patients at all levels of risk.<ref name="pmid16214597">{{cite journal |author=Baigent C, Keech A, Kearney PM, ''et al'' |title=Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins |journal=Lancet |volume=366 |issue=9493 |pages=1267-78 |year=2005 |pmid=16214597 |doi=10.1016/S0140-6736(05)67394-1}}</ref> | ||
Statins benefit patients with high [[fish oil]] consumption.<ref name="pmid17011942">{{cite journal |author=Nakamura H, Arakawa K, Itakura H, ''et al'' |title=Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial |journal=Lancet |volume=368 |issue=9542 |pages=1155–63 |year=2006 |month=September |pmid=17011942 |doi=10.1016/S0140-6736(06)69472-5 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69472-5 |issn=}}</ref> | Statins benefit patients with high [[fish oil]] consumption.<ref name="pmid17011942">{{cite journal |author=Nakamura H, Arakawa K, Itakura H, ''et al'' |title=Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial |journal=Lancet |volume=368 |issue=9542 |pages=1155–63 |year=2006 |month=September |pmid=17011942 |doi=10.1016/S0140-6736(06)69472-5 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(06)69472-5 |issn=}}</ref> | ||
| Line 14: | Line 15: | ||
===Niacin=== | ===Niacin=== | ||
==Uses== | |||
{{main|Hypercholesterolemia}} | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 09:11, 24 February 2010
In medicine, an anticholesteremic agent is any drug used to lower the serum cholesterol in the treatment of hypercholesterolemia."
Classification
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (Statins)
The U.S. Preventive Services Task Force (USPSTF) estimated that after 5 to 7 years of treatment with statins, the relative risk reduction of coronary heart disease events is decreased by approximately 30%[1][2]. More recently, a meta-analysis reported an almost identical relative risk reduction of 29.2% in low risk patients treated for 4.3 years [3]. A relative risk reduction of 19% in coronary mortality was found in a meta-analysis of patients at all levels of risk.[4]
Statins benefit patients with high fish oil consumption.[5]
Fibrates
Fibrates (fibric acid derivatives)
Bile acid sequestrants
Niacin
Uses
References
- ↑ Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN (2001). "Screening and treating adults for lipid disorders". American Journal of Preventive Medicine 20: 77–89. PMID 11306236. [e]
- ↑ Screening for Lipid Disorders: Recommendations and Rationale. Retrieved on 2007-10-17.
- ↑ Thavendiranathan P, Bagai A, Brookhart M, Choudhry N (2006). "Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials". Arch Intern Med 166: 2307-13. DOI:10.1001/archinte.166.21.2307. PMID 17130382. Research Blogging.
- ↑ Baigent C, Keech A, Kearney PM, et al (2005). "Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins". Lancet 366 (9493): 1267-78. DOI:10.1016/S0140-6736(05)67394-1. PMID 16214597. Research Blogging.
- ↑ Nakamura H, Arakawa K, Itakura H, et al (September 2006). "Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial". Lancet 368 (9542): 1155–63. DOI:10.1016/S0140-6736(06)69472-5. PMID 17011942. Research Blogging.